Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 μg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients

Respiration

Volumn 72, Issue SUPPL. 1, 2005, Pages 20-27

  Dusser, D ^a   Vicaut, E ^b   Lefrancois G ^c  

^a Hôpital Cochin ^*  (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c Chiesi   (France)

Author keywords

Asthma; Dry powder inhalers; Formoterol; Hydrofluoroalkanes; Non inferiority; Pressurized metered dose inhalers

Indexed keywords

FORMOTEROL; NORFLURANE;

ADULT; ARTICLE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL DOCUMENTATION; MODERATE PERSISTENT ASTHMA; MULTICENTER STUDY; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; POWDER INHALER; PREDICTION; PRIORITY JOURNAL; SAMPLE SIZE; SEVERE PERSISTENT ASTHMA; TREMOR;

ADULT; AEROSOL PROPELLANTS; AGED; ASTHMA; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYDROCARBONS, FLUORINATED; MALE; METERED DOSE INHALERS; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PEAK EXPIRATORY FLOW RATE; POWDERS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 20944450330     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083689     Document Type: Article

References (17)

1. Bousquet J: Introduction. Modulite: simplifying the changeover. Respir Med 2002;96:S1-S2.
2. Kesten S, Elias M, Cartier A, Chapman KR: Patient handling of a multidose dry powder inhalation device for albuterol. Chest 1994;105:1077-1081.
3. Global Initiative for Asthma: Global strategy for asthma management and prevention. National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) 2002, pp 1-192.
4. Ahnve S: Correction of QT interval for heart rate: Review of different formulas and the use of Bazett's formula in myocardial infarction. American Heart Journal 1985;109:568-574.
5. Global Initiative for Asthma: Global strategy for asthma management and prevention (2003 update). National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) 2003, pp 1-197.
6. Meyer JM, Wenzel CL, Kradjan WA: Salmeterol: A novel, long-acting beta 2-agonist. Ann Pharmacother 1993;27:1478-1487.
7. Bartow RA, Brogden RN: Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs 1998;55:303-322.
8. Ferrari M, Segattini C, Zanon R, Bertaiola M, Balestreri F, Brotto E, Lo Cascio V: Comparison of the protective effect of formoterol and of salmeterol against exercise-induced bronchospasm when given immediately before cycloergometric test. Respiration 2002;69:509-512.
9. Montreal Protocol on substances that deplete the ozone layer [Accessed 2002, Apr 19] on line. Available from: http://www.unep.org/ozone/pdf/Montreal- Protocol2000.pdf.
10. Nielsen KG, Skov M, Klug B, Ifversen M, Bisgaard H: Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer®. Eur Respir J 1997;10:2105-2109.
11. Smith KJ, Chan H-K, Brown KF: Influence of flow rate on aerosol particle size distributions from pressurized and breath-actuated inhalers. J Aerosol Med 1998;11:231-245.
12. Borgstrom L, Bondesson E, Moren F, Trofast E, Newman SP: Lung deposition of budesonide inhaled via turbuhaler: A comparison with terbutaline sulphate in normal subjects. Eur Respir J 1994;7:69-73.
13. Partridge MR: The transition in practice: Health professionals and patients. Br J Clin Pract 1997:32-36.
14. Hartung TK, Allbutt H, Dewar M, Innes JA, Crompton GK: Moving from CFC aerosol to HFA aerosol or dry powder inhalers: What do patients think? Respiration 2002;69:314-319.
15. Leach CL, Davidson PJ, Boudreau RJ: Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998;12:1346-1353.
16. Vignola AM, Bousquet J, Chanez P, Gagliardo R, Merendino AM, Chiappara G, Bonsignore G: Assessment of airway inflammation in asthma. Am J Respir Crit Care Med 1998;157:S184-S187.
17. Ullman A, Lofdahl CG, Melander B, Svedmyr N: Formoterol inhaled as dry powder or via pressurized metered-dose inhaler in a cumulative dose-response study. Allergy 1996;51:745-748.